Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate

被引：56

作者：

Fujiwara, M

Ijichi, K

Tokuhisa, K

Katsuura, K

Shigeta, S

Konno, K

Wang, GYS

Uemura, D

Yokota, T

Baba, M

机构：

[1] FUKUSHIMA MED COLL,DEPT MICROBIOL,MATSUKAWA 96012,FUKUSHIMA,JAPAN

[2] TOSOH CO LTD,TOKYO RES LAB,KANAGAWA 252,JAPAN

[3] SHIZUOKA UNIV,FAC LIBERAL ARTS,SHIZUOKA 422,JAPAN

[4] SAGAMI CHEM RES CTR,KANAGAWA 229,JAPAN

[5] KAGOSHIMA UNIV,FAC MED,CTR CHRON VIRAL DIS,DIV HUMAN RETROVIRUSES,KAGOSHIMA 890,JAPAN

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1996年 / 40卷 / 01期

关键词：

D O I：

10.1128/AAC.40.1.271

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ingenol 3,5,20-triacetate (ITA), one of the ingenol derivatives, is a selective inhibitor of human immunodeficiency virus (HIV) replication in vitro. ITA inhibited the replication of HIV strains in MT-4 cells at concentrations of 0.051 to 0.65 mu M. This concentration was approximately 10(3)-fold lower than its cytotoxic threshold. The mechanism of action of ITA is primarily attributed to the inhibition of viral adsorption to the host cells, but it is distinct from the mechanism of inhibition by other adsorption inhibitors.

引用

收藏

页码：271 / 273

页数：3

相关论文

共 22 条

[1]

BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493

[2] PRECLINICAL EVALUATION OF MKC-442, A HIGHLY POTENT AND SPECIFIC INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN-VITRO [J].

BABA, M ;

SHIGETA, S ;

YUASA, S ;

TAKASHIMA, H ;

SEKIYA, K ;

UBASAWA, M ;

TANAKA, H ;

MIYASAKA, T ;

WALKER, RT ;

DECLERCQ, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :688-692

[3] POTENT AND SELECTIVE-INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) BY 5-ETHYL-6-PHENYLTHIOURACIL DERIVATIVES THROUGH THEIR INTERACTION WITH THE HIV-1 REVERSE-TRANSCRIPTASE [J].

BABA, M ;

DECLERCQ, E ;

TANAKA, H ;

UBASAWA, M ;

TAKASHIMA, H ;

SEKIYA, K ;

NITTA, I ;

UMEZU, K ;

NAKASHIMA, H ;

MORI, S ;

SHIGETA, S ;

WALKER, RT ;

MIYASAKA, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (06) :2356-2360

[4]

BABA M, 1983, P NATL ACAD SCI USA, V85, P5132

[5] T-CELL ACTIVATION ANTIGEN, CD26, AS A COFACTOR FOR ENTRY OF HIV IN CD4+ CELLS [J].

CALLEBAUT, C ;

KRUST, B ;

JACOTOT, E ;

HOVANESSIAN, AG .

SCIENCE, 1993, 262 (5142) :2045-2050

[6]

CHOWDHURY MIH, 1990, VIROLOGY, V176, P126

[7] PREVENTION OF ACTIVATION OF HIV-1 BY ANTIVIRAL AGENTS IN OM-10.1 CELLS [J].

FEORINO, PM ;

BUTERA, ST ;

FOLKS, TM ;

SCHINAZI, RF .

ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1993, 4 (01) :55-63

[8] THE PHORBOL ESTER PHORBOL-MYRISTATE ACETATE INHIBITS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE-MEDIATED FUSION BY MODULATING AN ACCESSORY COMPONENT(S) IN CD4-EXPRESSING CELLS [J].

GOLDING, H ;

MANISCHEWITZ, J ;

VUJCIC, L ;

BLUMENTHAL, R ;

DIMITROV, DS .

JOURNAL OF VIROLOGY, 1994, 68 (03) :1962-1969

[9] A NONPROMOTING PHORBOL FROM THE SAMOAN MEDICINAL PLANT HOMALANTHUS-NUTANS INHIBITS CELL KILLING BY HIV-1 [J].

GUSTAFSON, KR ;

CARDELLINA, JH ;

MCMAHON, JB ;

GULAKOWSKI, RJ ;

ISHITOYA, J ;

SZALLASI, Z ;

LEWIN, NE ;

BLUMBERG, PM ;

WEISLOW, OS ;

BEUTLER, JA ;

BUCKHEIT, RW ;

CRAGG, GM ;

COX, PA ;

BADER, JP ;

BOYD, MR .

JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (11) :1978-1986

[10]

HASLER CM, 1992, CANCER RES, V52, P202